A combination of Botulinum Toxin A therapy and Functional Electrical Stimulation in children with cerebral palsy--a pilot study.
BACKGROUND
Among the ambulant population of children with spastic cerebral palsy (CP), dynamic equinus is one of the most common form of gait deviation that is encountered.


OBJECTIVE
To investigate the combined effects of Functional Electrical Stimulation (FES) and Botulinum Toxin A (BTXA) therapy in children with spastic CP, and to demonstrate the feasibility of this combination therapy.


METHODS
A single-subject design with repeated measures was adopted. Eight children (six males, two females; mean age 7 y 9 mo, SD 1 y 5 mo; range 7 y to 11 y) diagnosed with hemiplegic (n=6) or diplegic (n=2) spastic CP completed the study. Each subject participated in the study for twenty weeks. This period consisted of baseline (one week), BTXA phase (three weeks), first FES phase (four weeks), first control phase (four weeks), second FES phase (four weeks) and second control phase (four weeks). Subjects were assessed at the end of each phase. The ankle angle at the end of swing phase was selected as the primary outcome measure. The secondary outcome measure recorded was the foot contact pattern.


RESULTS
There was an increase in ankle dorsiflexion at the end of the combined intervention in most subjects (n=6), accompanied by an improvement in foot contact pattern.


CONCLUSIONS
This pilot study demonstrated that it is feasible to combine BTXA therapy with FES in ambulant children with spastic CP.
Bioengineering Unit, University of Strathclyde, Royal Hospital for Sick Children, Yorkhill Hospitals, Glasgow, UK. sujay.galen@strath.ac.uk
Sujay
S
Galen
Laura
L
Wiggins
Robert
R
McWilliam
Malcolm
M
Granat
D019274:Botulinum Toxins, Type A / Q000008:administration & dosage / Q000627:therapeutic use*; D002547:Cerebral Palsy / Q000503:physiopathology / Q000534:rehabilitation*; D002648:Child; D003131:Combined Modality Therapy; D004599:Electric Stimulation Therapy; D005260:Female; D020233:Gait Disorders, Neurologic / Q000503:physiopathology / Q000534:rehabilitation*; D006801:Humans; D007273:Injections, Intramuscular; D008297:Male; D009128:Muscle Spasticity / Q000503:physiopathology / Q000534:rehabilitation; D011446:Prospective Studies; D012606:Scotland
D019274:Botulinum Toxins, Type A